Sagimet Biosciences Inc. (SGMT)

Sagimet Biosciences Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	-	2	-	-	-
Gross Profit	-	2	-	-	-
Selling, General & Admin	16.01	12.96	6.14	4.38	3.22
Research & Development	38.44	19.78	24.92	19.34	8.18
Operating Expenses	54.45	32.74	31.06	23.72	11.4
Operating Income	-54.45	-30.74	-31.06	-23.72	-11.4
Interest & Investment Income	8.89	2.86	0.55	0.03	0.03
Other Non Operating Income (Expenses)	-	0	0	-0.75	-
EBT Excluding Unusual Items	-45.57	-27.88	-30.5	-24.44	-11.37
Pretax Income	-45.57	-27.88	-30.5	-24.44	-11.37
Net Income	-45.57	-27.88	-30.5	-24.44	-11.37
Net Income to Common	-45.57	-27.88	-30.5	-24.44	-11.37
Shares Outstanding (Basic)	31	10	0	0	0
Shares Outstanding (Diluted)	31	10	0	0	0
Shares Change (YoY)	199.71%	5565.90%	50.61%	26.95%	-
EPS (Basic)	-1.45	-2.66	-165.20	-199.40	-117.75
EPS (Diluted)	-1.45	-2.66	-165.20	-199.40	-117.75
Gross Margin	-	100.00%	-	-	-
Operating Margin	-	-1537.00%	-	-	-
Profit Margin	-	-1393.80%	-	-	-
EBITDA	-	-	-	-	-11.4
D&A For EBITDA	-	-	-	-	0
EBIT	-54.45	-30.74	-31.06	-23.72	-11.4

Updated Mar 12, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q